Cargando…
Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study
Introduction: Chronic osteomyelitis is a challenging condition in the orthopedic practice and traditionally treated using local and systemic antibiotics in a two-stage surgical procedure. With the introduction of the antimicrobial biomaterial S53P4 bioactive glass (Bonalive(®)), chronic osteomyeliti...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Copernicus GmbH
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600462/ https://www.ncbi.nlm.nih.gov/pubmed/34804776 http://dx.doi.org/10.5194/jbji-6-413-2021 |
_version_ | 1784601159982383104 |
---|---|
author | Van Vugt, Tom A. G. Heidotting, Jeffrey Arts, Jacobus J. Ploegmakers, Joris J. W. Jutte, Paul C. Geurts, Jan A. P. |
author_facet | Van Vugt, Tom A. G. Heidotting, Jeffrey Arts, Jacobus J. Ploegmakers, Joris J. W. Jutte, Paul C. Geurts, Jan A. P. |
author_sort | Van Vugt, Tom A. G. |
collection | PubMed |
description | Introduction: Chronic osteomyelitis is a challenging condition in the orthopedic practice and traditionally treated using local and systemic antibiotics in a two-stage surgical procedure. With the introduction of the antimicrobial biomaterial S53P4 bioactive glass (Bonalive(®)), chronic osteomyelitis can be treated in a one-stage procedure. This study evaluated the mid-term clinical results of patients treated with S53P4 bioactive glass for long bone chronic osteomyelitis. Methods: In this prospective multi-center study, patients from two different university medical centers in the Netherlands were included. One-stage treatment consisted of debridement surgery, implantation of S53P4 bioactive glass, and treatment with culture-based systemic antibiotics. If required, wound closure by a plastic surgeon was performed. The primary outcome was the eradication of infection, and a secondary statistical analysis was performed on probable risk factors for treatment failure. Results: In total, 78 patients with chronic cavitary long bone osteomyelitis were included. Follow-up was at least 12 months (mean 46; standard deviation, SD, 20), and 69 patients were treated in a one-stage procedure. Overall infection eradication was 85 %, and 1-year infection-free survival was 89 %. Primary closure versus local/muscular flap coverage is the only risk factor for treatment failure. Conclusion: With 85 % eradication of infection, S53P4 bioactive glass is an effective biomaterial in the treatment of chronic osteomyelitis in a one-stage procedure. A major risk factor for treatment failure is the necessity for local/free muscle flap coverage. These results confirm earlier published data, and together with the fundamentally different antimicrobial pathways without antibiotic resistance, S53P4 bioactive glass is a recommendable biomaterial for chronic osteomyelitis treatment and might be beneficial over other biomaterials. |
format | Online Article Text |
id | pubmed-8600462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Copernicus GmbH |
record_format | MEDLINE/PubMed |
spelling | pubmed-86004622021-11-19 Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study Van Vugt, Tom A. G. Heidotting, Jeffrey Arts, Jacobus J. Ploegmakers, Joris J. W. Jutte, Paul C. Geurts, Jan A. P. J Bone Jt Infect Original Full-Length Article Introduction: Chronic osteomyelitis is a challenging condition in the orthopedic practice and traditionally treated using local and systemic antibiotics in a two-stage surgical procedure. With the introduction of the antimicrobial biomaterial S53P4 bioactive glass (Bonalive(®)), chronic osteomyelitis can be treated in a one-stage procedure. This study evaluated the mid-term clinical results of patients treated with S53P4 bioactive glass for long bone chronic osteomyelitis. Methods: In this prospective multi-center study, patients from two different university medical centers in the Netherlands were included. One-stage treatment consisted of debridement surgery, implantation of S53P4 bioactive glass, and treatment with culture-based systemic antibiotics. If required, wound closure by a plastic surgeon was performed. The primary outcome was the eradication of infection, and a secondary statistical analysis was performed on probable risk factors for treatment failure. Results: In total, 78 patients with chronic cavitary long bone osteomyelitis were included. Follow-up was at least 12 months (mean 46; standard deviation, SD, 20), and 69 patients were treated in a one-stage procedure. Overall infection eradication was 85 %, and 1-year infection-free survival was 89 %. Primary closure versus local/muscular flap coverage is the only risk factor for treatment failure. Conclusion: With 85 % eradication of infection, S53P4 bioactive glass is an effective biomaterial in the treatment of chronic osteomyelitis in a one-stage procedure. A major risk factor for treatment failure is the necessity for local/free muscle flap coverage. These results confirm earlier published data, and together with the fundamentally different antimicrobial pathways without antibiotic resistance, S53P4 bioactive glass is a recommendable biomaterial for chronic osteomyelitis treatment and might be beneficial over other biomaterials. Copernicus GmbH 2021-11-12 /pmc/articles/PMC8600462/ /pubmed/34804776 http://dx.doi.org/10.5194/jbji-6-413-2021 Text en Copyright: © 2021 Tom A. G. Van Vugt et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Full-Length Article Van Vugt, Tom A. G. Heidotting, Jeffrey Arts, Jacobus J. Ploegmakers, Joris J. W. Jutte, Paul C. Geurts, Jan A. P. Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study |
title | Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study |
title_full | Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study |
title_fullStr | Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study |
title_full_unstemmed | Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study |
title_short | Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study |
title_sort | mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using s53p4 bioactive glass: a multi-center study |
topic | Original Full-Length Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600462/ https://www.ncbi.nlm.nih.gov/pubmed/34804776 http://dx.doi.org/10.5194/jbji-6-413-2021 |
work_keys_str_mv | AT vanvugttomag midtermclinicalresultsofchroniccavitarylongboneosteomyelitistreatmentusings53p4bioactiveglassamulticenterstudy AT heidottingjeffrey midtermclinicalresultsofchroniccavitarylongboneosteomyelitistreatmentusings53p4bioactiveglassamulticenterstudy AT artsjacobusj midtermclinicalresultsofchroniccavitarylongboneosteomyelitistreatmentusings53p4bioactiveglassamulticenterstudy AT ploegmakersjorisjw midtermclinicalresultsofchroniccavitarylongboneosteomyelitistreatmentusings53p4bioactiveglassamulticenterstudy AT juttepaulc midtermclinicalresultsofchroniccavitarylongboneosteomyelitistreatmentusings53p4bioactiveglassamulticenterstudy AT geurtsjanap midtermclinicalresultsofchroniccavitarylongboneosteomyelitistreatmentusings53p4bioactiveglassamulticenterstudy |